[en] The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The main characteristics of each molecule as well as its modalities of appropriate use in clinical practice will be pointed out.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Birkenhager W.H., De Leeuw P.W. (1999) Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertension 17:873-881.
Scheen A.J. (2000) Actualités thérapeutiques 2000. Rev Med Liège 55:852-861.
Scheen A.J. (2000) Le médicament du mois. La moxonidine (MoxonR). Rev Med Liège 55:61-63.
Scheen A.J. (2000) Le médicament du mois. La combinaison fixe dipyridamole-acide acétylsalicylique (AggrenoxR). Rev Med Liège 55:957-959.
Scheen A.J. (2001) Le médicament du mois. Le clopidogrel (Plavix®). Rev Med Liège 56:186-189.
Simonneau G., Sors H., Charbonnier B. (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 337:663-669.
Louis R. (2001) Le médicament du mois. Le montélukast (Singulair®). Rev Med Liège 56:460-462.
Scheen A.J. (1998) Le médicament du mois. Le formotérol (Oxis® TurbohalerTM). Rev Med Liège 53:715-718.
Lindberg P., Brändstrom A., Wallmark B. (1990) Omeprazole: The first proton pump inhibitor. Med Res Rev 10:1-54.
Lind T., Rydberg L., Kylebäck A. (2000) Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14:861-867.
Lanza F., Bardhan K.D., Perdomo C. (2001) Efficacy of rabeprazole once daily for acid-related disorders. Dig Dis Sci 46:587-596.
Louis E., Belaiche J. (2000) Reflux gastro-oesophagien de l'adulte: Diagnostic et traitement. Rev Med Liège 55:341-344.
Greenberg G.R., Feagan B.D., Martin F. (1994) Oral budesonide for active Crohn's disease. N Engl J Med 331:836-841.
Sadzot B. (2000) Le médicament du mois. Le topiramate (Topamax®). Rev Med Liège 55:114-116.
Scheen A.J. (1999) Actualite♂s the♂rapeutiques 1999. Rev Med Liège 54:725-734.
Christe W., Krämer G., Vigonius U. (1997) A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 26:451-460.
Dindemanse J. (1997) Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease. Drug Develop Res 42:1-25.
Colonna L., Saleem P., Dondey-Nouvel L. (2000) Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Pharmacol 15:13-22.
(2000) The role of mirtazapine in the pharmacotherapy of depression. J Clin Psychiatry 61:609-616.
Ansseau M. (1998) Le médicament du mois. La venlafaxine (Efexo®r). Rev Med Liège 53:106-108.
Cunningham L.A. (1997) Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 9:157-164.
Scheen A.J. (2000) Le médicament du mois. La Iévofloxacine (Tavanic®). Rev Med Liège 55:1015-1017.
Hann I.M., Prentice H.G. (2001) Lipid-based amphotericin B: A review of the last 10 years of use. Int J Antimicrob Agents 17:161-169.
Lepage Ph. (2001) Le médicament du mois. Le Meningitec®. Rev Med Liège 56:124-125.
Dagan R. (2000) Treatment of pediatric infectious diseases: Role of pneumococcal conjugate vaccines. Pediatr Infect Dis J 19(SUPPL.):371-397.
Scheen A.J. (2001) Le médicament du mois. Le répaglinide (NovoNorm®). Rev Med Liege 56:456-459.
Scheen A.J., Jandrain B.J., Paquot N. (2001) Le contrôle pharmacologique de l'hyperglycémie post-prandiale. Méd Hyg 59:1619-1624.
Gillies P.S., Dunn C.J. (2000) Pioglitazone. Drugs 60:333-343.
Scheen A.J. (2001) Thiazolidinediones and liver toxicity. Diab Metab 27:305-313.
Hermans M.P., Nobels R.F., De Leeuw I. (1999) Insulin lispro (HumalogR), a novel fast-acting insulin analogue for the treatment of diabetes mellitus: Overview of pharmacological and clinical data. Acta Clin Belg 54:233-240.
Home P.D., Lindholm A., Hylleberg B. (1998) Improved glycemic control with insulin Aspart. A multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 21:1904-1909.
McNeely W., Goa K.L. (1998) Sibutramine. A review of its contribution to the management of obesity. Drugs 56:1093-1124.
Scheen A.J. (2001) Après la tempête sur les anorexigènes centraux, l'étude "STORM" avec la sibutramine. Rev Med Liège 56:56-58.
Studd J., Pornel B., Marton I. (1999) Efficacy and acceptability of intranasal 17B-oestradiol for menopausal symptoms: Randomised dose-response study. Lancet 353:1574-1578.
Scheen A.J. (2001) Le médicament du mois. Le célécoxib (Celebrex®). Rev Med Liège 56:53-55.
Fitzgerald G.A., Patrono C. (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433-442.
Fox R.I. (1998) Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 25(SUPPL. 53):20-26.
(1999) Advances in targetted therapies: TNF-alpha blockade in clinical practice. Ann Rheum Dis 58(SUPPL. 1):1-130.
Maini R., St Clair E.W., Brredveld F. (1999) Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 354:1932-1940.
Moreland L., Schiff M.H., Baugartner S.W. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478-486.
Belaiche J., Louis E. (2000) Traitement de la maladie de Crohn de l'adulte par anticorps anti-tumor necrosis factor-alpha. Méd Hyg 58:1616-1621.
Gast P., Bours V., Detrooz B., Colette M.Y., Booz V. (2000) Recommandations en matière de traitement du cancer rectal. Rev Med Liège 55:350-355.
Budman D.R., Meropol N.J., Reigner B. (1998) Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 16:1795-1802.
Rustum Y.M. (1997) Mechanism-based improvement in the therapeutic selectivity of 5-FU alone and under conditions of metabolic modulation. Oncology 54(SUPPL. 1):7-11.
Jérusalem G., Bours V., Fillet G. (2000) Traitement adjuvant du cancer du sein: Méta-analyse et recommandations thérapeutiques. Rev Med Liège 55:356-359.
Cobleigh M.A., Vogel C.L., Tripathy D. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648.
McLaughlin P., Grillo-Lopez A.J., Link B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833.
Billaud E.M. (2000) Clinical pharmacology of immunosuppressive drugs: Year 2000 - Time for alternatives. Thérapie 55:177-183.
